582P Preclinical development of AT1412, a patient derived CD9 antibody that does not induce thrombosis for treatment of precursor B ALL

Villaudy, Julien; Schotte, Remko; Jong, Greta de; Neviani, Viviana; Pos, Wouter; Levie, Sophie E.; Yasuda, Etsuko; Cercel, Madalina G.; Szabó, Anikó; Fatmawati, Christien; Kedde, Martijn; Horbach, Sjeng; Verdegaal, Els M.E.; Helden, Pauline van; Burg, Sjoerd H. van der; Rijneveld, Anita W.; Gros, Piet; Spits, Hergen; Hazenberg, Mette D.; Eenennaam, Hans van

doi:10.1016/j.annonc.2020.08.696

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…177,198,199 A promising divalent anti-CD9 Ab is the AT1412 clone isolated from survivors of stage IV metastatic melanoma that did not induce platelet aggregation or thrombosis. 198,200,201 Although not experimentally evaluated, it is conceivable (and perhaps advantageous) that the development of bispecific Abs targeting CD9 and another tumor-associated antigen or one of its interacting partners (e.g. EWI-2, 24 EWI-F, 202 integrins), notably those involved in cell adhesion or migration, could improve the specific targeting and potentially interfere with cancer progression.…”

Section: Clinical Use Of Anti-cd9 Antibodies: Potential Toxicity and Perspectivesmentioning

confidence: 99%

CD9, a tetraspanin target for cancer therapy?

Lorico

Lorico-Rappa

Karbanová

et al. 2021

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

In the present minireview, we intend to provide a brief history of the field of CD9 involvement in oncogenesis and in the metastatic process of cancer, considering its potential value as a tumor-associated antigenic target. Over the years, CD9 has been identified as a favorable prognostic marker or predictor of metastatic potential depending on the cancer type. To understand its implications in cancer beside its use as an antigenic biomarker, it is essential to know its physiological functions, including its molecular partners in a given cell system. Moreover, the discovery that CD9 is one of the most specific and broadly expressed markers of extracellular membrane vesicles, nanometer-sized entities that are released into extracellular space and various physiological body fluids and play a role in intercellular communication under physiological and pathological conditions, notably the establishment of cancer metastases, has added a new dimension to our knowledge of CD9 function in cancer. Here, we will discuss these issues as well as the possible cancer therapeutic implications of CD9, their limitations, and pitfalls.

show abstract